132 related articles for article (PubMed ID: 36250599)
1. Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications.
Suriaga A; Tappen RM; Aston ER; Chiang-Hanisko L; Newman D
J Nurs Scholarsh; 2023 May; 55(3):623-636. PubMed ID: 36250599
[TBL] [Abstract][Full Text] [Related]
2. Surveillance for Violent Deaths - National Violent Death Reporting System, 34 States, Four California Counties, the District of Columbia, and Puerto Rico, 2017.
Petrosky E; Ertl A; Sheats KJ; Wilson R; Betz CJ; Blair JM
MMWR Surveill Summ; 2020 Dec; 69(8):1-37. PubMed ID: 33270620
[TBL] [Abstract][Full Text] [Related]
3. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
[TBL] [Abstract][Full Text] [Related]
4. Quantifying underreporting of law-enforcement-related deaths in United States vital statistics and news-media-based data sources: A capture-recapture analysis.
Feldman JM; Gruskin S; Coull BA; Krieger N
PLoS Med; 2017 Oct; 14(10):e1002399. PubMed ID: 29016598
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for Violent Deaths - National Violent Death Reporting System, 39 States, the District of Columbia, and Puerto Rico, 2018.
Sheats KJ; Wilson RF; Lyons BH; Jack SPD; Betz CJ; Fowler KA
MMWR Surveill Summ; 2022 Jan; 71(3):1-44. PubMed ID: 35085227
[TBL] [Abstract][Full Text] [Related]
6. Surveillance for Violent Deaths - National Violent Death Reporting System, 48 States, the District of Columbia, and Puerto Rico, 2020.
Liu GS; Nguyen BL; Lyons BH; Sheats KJ; Wilson RF; Betz CJ; Fowler KA
MMWR Surveill Summ; 2023 May; 72(5):1-38. PubMed ID: 37220104
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for Violent Deaths - National Violent Death Reporting System, 32 States, 2016.
Ertl A; Sheats KJ; Petrosky E; Betz CJ; Yuan K; Fowler KA
MMWR Surveill Summ; 2019 Oct; 68(9):1-36. PubMed ID: 31581165
[TBL] [Abstract][Full Text] [Related]
8. Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study.
Hobbs M; Patel R; Morrison PD; Kalk N; Stone JM
J Psychopharmacol; 2020 Jun; 34(6):648-653. PubMed ID: 32108548
[TBL] [Abstract][Full Text] [Related]
9. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for Violent Deaths - National Violent Death Reporting System, 42 States, the District of Columbia, and Puerto Rico, 2019.
Wilson RF; Liu G; Lyons BH; Petrosky E; Harrison DD; Betz CJ; Blair JM
MMWR Surveill Summ; 2022 May; 71(6):1-40. PubMed ID: 35588398
[TBL] [Abstract][Full Text] [Related]
11. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
12. Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States.
Roehler DR; Hoots BE; Vivolo-Kantor AM
Drug Alcohol Depend; 2020 Feb; 207():107810. PubMed ID: 31862557
[TBL] [Abstract][Full Text] [Related]
13. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
Cooper ZD
Curr Psychiatry Rep; 2016 May; 18(5):52. PubMed ID: 27074934
[TBL] [Abstract][Full Text] [Related]
14. Cannabis, cannabinoids, and health.
Lafaye G; Karila L; Blecha L; Benyamina A
Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
[TBL] [Abstract][Full Text] [Related]
15. Leading causes of death among decedents with mention of schizophrenia on the death certificates in the United States.
Lin JJ; Liang FW; Li CY; Lu TH
Schizophr Res; 2018 Jul; 197():116-123. PubMed ID: 29395608
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
17. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
Winstock A; Lynskey M; Borschmann R; Waldron J
J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
[TBL] [Abstract][Full Text] [Related]
18. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016.
Springer YP; Gerona R; Scheunemann E; Shafer SL; Lin T; Banister SD; Cooper MP; Castrodale LJ; Levy M; Butler JC; McLaughlin JB
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(40):1108-1111. PubMed ID: 27736839
[TBL] [Abstract][Full Text] [Related]
19. Rural and Urban Differences in Passenger-Vehicle-Occupant Deaths and Seat Belt Use Among Adults - United States, 2014.
Beck LF; Downs J; Stevens MR; Sauber-Schatz EK
MMWR Surveill Summ; 2017 Sep; 66(17):1-13. PubMed ID: 28934184
[TBL] [Abstract][Full Text] [Related]
20. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A; Mann CL; Spriggs S; DeFrancisco DR; Carbonaro S; Parvez L; Galynker II; Perkel CA; Hurd YL
J Clin Psychiatry; 2019 Jul; 80(4):. PubMed ID: 31265768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
